The FDA lists a Class II recall, dated 9 September and ongoing, of Baxter's dexmedetomidine 400 micrograms in 100 mL sodium chloride (4 micrograms per mL) in Galaxy single-dose containers, for current good manufacturing practice deviations. Class II means use may cause temporary or medically reversible effects, or that serious harm is remote.
The notice concerns US distribution. Theatres and ICUs using premixed dexmedetomidine should check their stock against the recalled product and lot details through their pharmacy.
- Ask pharmacy to check premixed dexmedetomidine stock against the recalled Baxter product and lots.
- Quarantine any affected bags and use an alternative supply.
- Report any adverse event linked to the product through your pharmacovigilance system.
- Note that the recall concerns manufacturing practice, not a new safety finding about dexmedetomidine itself.
Why it matters
Premixed bags are widely used in theatre and ICU sedation, so an unnoticed recall can reach patients quickly.
Don't overread it
A manufacturing-practice recall is not evidence that dexmedetomidine is unsafe.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for anaesthesiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free